Andrew J. McLachlan

22.0k total citations · 4 hit papers
450 papers, 15.5k citations indexed

About

Andrew J. McLachlan is a scholar working on Pharmacology, Geriatrics and Gerontology and Pharmacology. According to data from OpenAlex, Andrew J. McLachlan has authored 450 papers receiving a total of 15.5k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Pharmacology, 97 papers in Geriatrics and Gerontology and 72 papers in Pharmacology. Recurrent topics in Andrew J. McLachlan's work include Pharmaceutical Practices and Patient Outcomes (93 papers), Musculoskeletal pain and rehabilitation (55 papers) and Health Systems, Economic Evaluations, Quality of Life (48 papers). Andrew J. McLachlan is often cited by papers focused on Pharmaceutical Practices and Patient Outcomes (93 papers), Musculoskeletal pain and rehabilitation (55 papers) and Health Systems, Economic Evaluations, Quality of Life (48 papers). Andrew J. McLachlan collaborates with scholars based in Australia, United States and United Kingdom. Andrew J. McLachlan's co-authors include Richard O. Day, Christopher G. Maher, David G. Le Couteur, Sarah N. Hilmer, Vasi Naganathan, Jo‐anne E Brien, Kenneth M. Williams, Alemayehu Mekonnen, Michael Dolton and Danijela Gnjidic and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Andrew J. McLachlan

435 papers receiving 15.0k citations

Hit Papers

Polypharmacy cutoff and o... 2012 2026 2016 2021 2012 2015 2016 2014 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes
    2012 843 citations Danijela Gnjidic, Sarah N. Hilmer et al. profile →
  2. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials
    2015 383 citations Christopher G. Maher, Paulo H. Ferreira et al. profile →
  3. Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis
    2016 340 citations Alemayehu Mekonnen, Andrew J. McLachlan et al. BMJ Open profile →
  4. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies
    2014 339 citations Nicole Lowres, Lis Neubeck et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew J. McLachlan Australia 64 3.6k 3.6k 2.1k 1.9k 1.6k 450 15.5k
Toine C. G. Egberts Netherlands 72 3.2k 0.9× 2.0k 0.6× 1.7k 0.8× 1.2k 0.7× 1.4k 0.8× 512 18.2k
Paula A. Rochon Canada 73 3.5k 1.0× 1.7k 0.5× 2.3k 1.1× 881 0.5× 1.9k 1.2× 382 18.0k
Walter E. Haefeli Germany 62 2.1k 0.6× 1.1k 0.3× 968 0.5× 1.8k 1.0× 2.0k 1.2× 532 15.3k
Wayne A. Ray United States 75 2.1k 0.6× 3.9k 1.1× 2.3k 1.1× 1.3k 0.7× 1.8k 1.1× 215 21.5k
David N. Juurlink Canada 62 1.9k 0.5× 2.5k 0.7× 892 0.4× 1.1k 0.6× 2.2k 1.4× 344 17.0k
Miriam Sturkenboom Netherlands 68 1.1k 0.3× 3.0k 0.8× 1.4k 0.7× 692 0.4× 2.1k 1.3× 461 18.0k
Jesper Hallas Denmark 61 2.1k 0.6× 1.3k 0.3× 1.6k 0.8× 673 0.4× 2.3k 1.5× 476 17.4k
Jeffrey K Aronson United Kingdom 47 1.8k 0.5× 1.2k 0.3× 1.4k 0.7× 909 0.5× 658 0.4× 327 11.6k
G. Caleb Alexander United States 66 2.1k 0.6× 1.2k 0.3× 2.7k 1.3× 830 0.4× 2.4k 1.5× 355 16.8k
Munir Pirmohamed United Kingdom 88 2.7k 0.8× 7.6k 2.1× 2.1k 1.0× 8.6k 4.5× 2.8k 1.8× 601 34.5k

Countries citing papers authored by Andrew J. McLachlan

Since Specialization
Citations

This map shows the geographic impact of Andrew J. McLachlan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew J. McLachlan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew J. McLachlan more than expected).

Fields of papers citing papers by Andrew J. McLachlan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew J. McLachlan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew J. McLachlan. The network helps show where Andrew J. McLachlan may publish in the future.

Co-authorship network of co-authors of Andrew J. McLachlan

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew J. McLachlan. A scholar is included among the top collaborators of Andrew J. McLachlan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew J. McLachlan. Andrew J. McLachlan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hilmer, Sarah N., Mouna Sawan, Patrick J. Kelly, et al.. (2024). Prevalence of Adverse Drug Reactions in Hospital Among Older Patients with and Without Dementia. Drugs & Aging. 41(10). 833–846. 2 indexed citations
2.
Galettis, Peter, et al.. (2023). Comparison of capecitabine concentrations determined by microsampling versus plasma concentrations for therapeutic drug monitoring: a pilot study. Journal of Pharmacy and Pharmacology. 76(2). 86–92. 1 indexed citations
3.
Roberts, Daniel K., Stephanie Mathieson, Daniel Steffens, et al.. (2022). Pain, pain management and related outcomes following pelvic exenteration surgery: a systematic review. Colorectal Disease. 25(4). 562–572. 3 indexed citations
4.
5.
Etherton‐Beer, Christopher, Amy Page, Andrew J. McLachlan, et al.. (2022). Deprescribing for older people living in residential aged care facilities: Pharmacist recommendations, doctor acceptance and implementation. Archives of Gerontology and Geriatrics. 107. 104910–104910. 19 indexed citations
6.
Schultz, Hayley B., et al.. (2022). Population Pharmacokinetics of Oral-Based Administration of Cannabidiol in Healthy Adults: Implications for Drug Development. Cannabis and Cannabinoid Research. 8(5). 877–886. 6 indexed citations
7.
Chow, Michael Y.T., Rachel Yoon Kyung Chang, Mengyu Li, et al.. (2020). Pharmacokinetics and Time-Kill Study of Inhaled Antipseudomonal Bacteriophage Therapy in Mice. Antimicrobial Agents and Chemotherapy. 65(1). 41 indexed citations
8.
McLachlan, Andrew J., et al.. (2017). The role of ethnicity in personalized dosing of small molecule tyrosine kinase inhibitors used in oncology. Translational Cancer Research. 6. 6 indexed citations
9.
Mathieson, Stephanie, Lisa Valenti, Christopher G. Maher, et al.. (2017). Worsening trends in analgesics recommended for spinal pain in primary care. European Spine Journal. 27(5). 1136–1145. 32 indexed citations
10.
Mekonnen, Alemayehu, et al.. (2016). Medication reconciliation as a medication safety initiative in Ethiopia: a study protocol. BMJ Open. 6(11). e012322–e012322. 11 indexed citations
11.
Page, Amy, Kathleen N. Potter, Rhonda Clifford, Andrew J. McLachlan, & Christopher Etherton‐Beer. (2015). Prescribing for Australians living with dementia: study protocol using the Delphi technique. BMJ Open. 5(8). e008048–e008048. 40 indexed citations
12.
Dolton, Michael, Roger J. M. Brüggemann, David M. Burger, & Andrew J. McLachlan. (2014). Understanding Variability in Posaconazole Exposure Using an Integrated Population Pharmacokinetic Analysis. Antimicrobial Agents and Chemotherapy. 58(11). 6879–6885. 66 indexed citations
13.
Chan, John Gar Yan, Angel Pang, Andrew J. McLachlan, et al.. (2014). Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. International Journal of Antimicrobial Agents. 45(3). 319–323. 13 indexed citations
14.
Dolton, Michael, Vidya Perera, Lisa Pont, & Andrew J. McLachlan. (2013). Terbinafine in Combination with Other Antifungal Agents for Treatment of Resistant or Refractory Mycoses: Investigating Optimal Dosing Regimens Using a Physiologically Based Pharmacokinetic Model. Antimicrobial Agents and Chemotherapy. 58(1). 48–54. 32 indexed citations
15.
Pinto, Rafael Zambelli, Christopher G. Maher, Manuela L. Ferreira, et al.. (2012). Drugs for relief of pain in patients with sciatica: systematic review and meta-analysis. BMJ. 344(feb13 1). e497–e497. 154 indexed citations
16.
17.
Stocker, Sophie L., Andrew J. McLachlan, Radojka M. Savić, et al.. (2012). The pharmacokinetics of oxypurinol in people with gout. British Journal of Clinical Pharmacology. 74(3). 477–489. 25 indexed citations
18.
Tan, Sim Yee, et al.. (2011). An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. Expert Opinion on Drug Metabolism & Toxicology. 7(11). 1395–1410. 19 indexed citations
19.
Hong, Ying, Peter J. Shaw, Christa E. Nath, et al.. (2006). Population Pharmacokinetics of Liposomal Amphotericin B in Pediatric Patients with Malignant Diseases. Antimicrobial Agents and Chemotherapy. 50(3). 935–942. 75 indexed citations
20.
McLachlan, Andrew J. & Susan E. Tett. (1998). Effect of Metabolic Inhibitors on Cyclosporine Pharmacokinetics Using a Population Approach. Therapeutic Drug Monitoring. 20(4). 390–395. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toine C. G. Egberts Breakdown of academic impact, for papers by Paula A. Rochon Breakdown of academic impact, for papers by Walter E. Haefeli Breakdown of academic impact, for papers by Wayne A. Ray Breakdown of academic impact, for papers by David N. Juurlink Breakdown of academic impact, for papers by Miriam Sturkenboom Breakdown of academic impact, for papers by Jesper Hallas Breakdown of academic impact, for papers by Jeffrey K Aronson Breakdown of academic impact, for papers by G. Caleb Alexander Breakdown of academic impact, for papers by Munir Pirmohamed
Rankless by CCL
2026